FMP
Benitec Biopharma Inc.
BNTC
NASDAQ
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
10.75 USD
0.03 (0.279%)
We are unable to load the chart at this time.
Dr. Jerel A. Banks M.D., Ph.D.
Healthcare
Biotechnology
NASDAQ
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
0001808898
US08205P2092
08205P100
3940 Trust Way
510 780 0819
US
16
Jun 24, 2014
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001808898
NASDAQ
Biotechnology
Healthcare
08205P100
US08205P2092
US
10.75
0.88
54.46k
249.58M
-
2.7-13.29
6.32
-
-
-
-
-3.66
-
https://benitec.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.